Free Trial

StockNews.com Begins Coverage on Global Cord Blood (NYSE:CO)

Global Cord Blood logo with Medical background

StockNews.com began coverage on shares of Global Cord Blood (NYSE:CO - Free Report) in a research note issued to investors on Wednesday. The firm issued a strong-buy rating on the medical research company's stock.

Global Cord Blood Stock Performance

Shares of Global Cord Blood stock remained flat at $1.50 on Wednesday. The stock had a trading volume of 2,131 shares, compared to its average volume of 216,519. The stock has a market capitalization of $182.33 million, a price-to-earnings ratio of 2.34 and a beta of 0.16. Global Cord Blood has a fifty-two week low of $2.03 and a fifty-two week high of $5.50. The stock has a fifty day moving average price of $1.31 and a 200-day moving average price of $1.40.

About Global Cord Blood

(Get Free Report)

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.

Read More

Should You Invest $1,000 in Global Cord Blood Right Now?

Before you consider Global Cord Blood, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Global Cord Blood wasn't on the list.

While Global Cord Blood currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Crypto Boom 2025: Bitcoin’s Rise and Trump’s Impact on the Market
Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines